In a study with AI to analyze serum tumor markers (CA19-9, CA125, CEA), the 913 serum samples from PC patients and non-PC patients were randomly divided into a training group (sample size of 658) and a test group (sample size of 255). This evidence concerns the gene CEACAM5 and pachyonychia congenita.